



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2010	2009	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾					
SKIN CARE					
US	452	423	6.9%	6.9%	-
Intl	468	419	11.7%	2.4%	9.3%
WW	920	842	9.3%	4.6%	4.7%
BABY CARE					
US	103	102	1.0%	1.0%	-
Intl	426	387	10.1%	1.2%	8.9%
WW	529	489	8.2%	1.2%	7.0%
ORAL CARE					
US	174	188	-7.4%	-7.4%	-
Intl	207	177	16.9%	5.1%	11.8%
WW	381	365	4.4%	-1.3%	5.7%
OTC/NUTRITIONALS					
US	542	726	-25.3%	-25.3%	-
Intl	665	622	6.9%	-2.7%	9.6%
WW	1,207	1,348	-10.5%	-15.0%	4.5%
WOMEN'S HEALTH					
US	146	149	-2.0%	-2.0%	-
Intl	323	274	17.9%	7.8%	10.1%
WW	469	423	10.9%	4.4%	6.5%
WOUND CARE / OTHER					
US	143	138	3.6%	3.6%	-
Intl	117	106	10.4%	-	10.4%
WW	260	244	6.6%	2.1%	4.5%
TOTAL CONSUMER					
US	1,560	1,726	-9.6%	-9.6%	-
Intl	2,206	1,985	11.1%	1.4%	9.7%
WW	3,766	3,711	1.5%	-3.7%	5.2%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2010	2009	% Change		
			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ^{(2) (5)}					
<u>ACIPHEX/PARIET</u>					
US	119	138	-13.8%	-13.8%	-
Intl	141	125	12.8%	3.1%	9.7%
WW	260	263	-1.1%	-5.7%	4.6%
<u>CONCERTA</u>					
US	231	269	-14.1%	-14.1%	-
Intl	98	75	30.7%	17.3%	13.4%
WW	329	344	-4.4%	-7.3%	2.9%
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>					
US	38	75	-49.3%	-49.3%	-
Intl	146	156	-6.4%	-13.4%	7.0%
WW	184	231	-20.3%	-25.1%	4.8%
<u>LEVAQUIN/FLOXIN</u>					
US	363	408	-11.0%	-11.0%	-
Intl	8	17	-52.9%	-56.3%	3.4%
WW	371	425	-12.7%	-12.8%	0.1%
<u>PREZISTA</u>					
US	89	72	23.6%	23.6%	-
Intl	98	50	96.0%	80.3%	15.7%
WW	187	122	53.3%	46.8%	6.5%
<u>PROCRIT/EPREX</u>					
US	290	321	-9.7%	-9.7%	-
Intl	233	229	1.7%	-6.2%	7.9%
WW	523	550	-4.9%	-8.2%	3.3%
<u>REMICADE</u>					
US	780	737	5.8%	5.8%	-
US Exports ⁽³⁾	400	286	39.9%	39.9%	-
Intl	6	5	20.0%	19.9%	0.1%
WW	1,186	1,028	15.4%	15.4%	-
<u>RISPERDAL/RISPERIDONE</u>					
US	5	118	-95.8%	-95.8%	-
Intl	133	157	-15.3%	-20.1%	4.8%
WW	138	275	-49.8%	-52.5%	2.7%
<u>RISPERDAL CONSTA</u>					
US	117	126	-7.1%	-7.1%	-
Intl	262	199	31.7%	21.4%	10.3%
WW	379	325	16.6%	10.3%	6.3%
<u>TOPAMAX</u>					
US	57	495	-88.5%	-88.5%	-
Intl	91	107	-15.0%	-21.6%	6.6%
WW	148	602	-75.4%	-76.6%	1.2%
<u>VELCADE</u>					
US	-	-	-	-	-
Intl	261	192	35.9%	26.3%	9.6%
WW	261	192	35.9%	26.3%	9.6%
<u>OTHER</u>					
US	717	629	14.0%	14.0%	-
Intl	955	794	20.3%	11.1%	9.2%
WW	1,672	1,423	17.5%	12.4%	5.1%
TOTAL PHARMACEUTICAL					
US	3,206	3,674	-12.7%	-12.7%	-
Intl	2,432	2,106	15.5%	6.6%	8.9%
WW	5,638	5,780	-2.5%	-5.7%	3.2%
MAJOR NEW PHARM PRODUCTS ⁽⁴⁾					
<u>INVEGA</u>					
US	69	66	4.5%	4.5%	-
Intl	39	25	56.0%	43.2%	12.8%
WW	108	91	18.7%	15.1%	3.6%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2010	2009	% Change		
			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾					
<u>CORDIS ⁽⁶⁾</u>					
US	251	246	2.0%	2.0%	-
Intl	421	422	-0.2%	-6.3%	6.1%
WW	672	668	0.6%	-3.3%	3.9%
<u>DEPUY</u>					
US	814	766	6.3%	6.3%	-
Intl	640	526	21.7%	11.2%	10.5%
WW	1,454	1,292	12.5%	8.2%	4.3%
<u>DIABETES CARE</u>					
US	290	270	7.4%	7.4%	-
Intl	307	271	13.3%	5.4%	7.9%
WW	597	541	10.4%	6.4%	4.0%
<u>ETHICON</u>					
US	510	405	25.9%	25.9%	-
Intl	637	548	16.2%	7.6%	8.6%
WW	1,147	953	20.4%	15.5%	4.9%
<u>ETHICON ENDO-SURGERY</u>					
US	483	454	6.4%	6.4%	-
Intl	685	561	22.1%	12.9%	9.2%
WW	1,168	1,015	15.1%	10.0%	5.1%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>					
US	288	277	4.0%	4.0%	-
Intl	237	190	24.7%	16.1%	8.6%
WW	525	467	12.4%	8.9%	3.5%
<u>VISION CARE</u>					
US	249	234	6.4%	6.4%	-
Intl	415	365	13.7%	6.9%	6.8%
WW	664	599	10.9%	6.8%	4.1%
<u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u>					
US	2,886	2,652	8.8%	8.8%	-
Intl	3,341	2,883	15.9%	7.5%	8.4%
WW	6,227	5,535	12.5%	8.1%	4.4%

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Reported in U.S. sales

⁽⁴⁾ Included in Other

⁽⁵⁾ Prior year conforms to current year presentation

⁽⁶⁾ Includes sales of Drug-Eluting Stents for Q1 2010 of \$60, \$131 and \$191MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q1 2009 of \$67, \$184 and \$251MM Domestic, International and Worldwide respectively